Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments

Thrombocythemia, Essential Clinical Trial

Official title:
A Non-Interventional, Post Authorisation Safety Study, to Continuously Monitor Safety and Pregnancy Outcomes in a Cohort of At-Risk Essential Thrombocythaemia (ET) Subjects Exposed to Xagrid Compared to Other Conventional Cytoreductive Treatments

Status Completed

Clinical Trial Summary

This is an observational safety study being conducted in Europe comparing patients taking Xagrid to patients taking other cytoreductive treatments. The plan is to enrol at least 750 subjects taking Xagrid with up to 3000 subjects taking other cytoreductive therapies. The study will collect follow up data for 5 years for each patient enrolled that will focus on collecting data related to pre-defined events (PDEs) and Suspected Serious Adverse Reactions (SSARs).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00567502
Study type	Observational
Source	Takeda
Contact
Status	Completed
Phase
Start date	May 31, 2005
Completion date	April 30, 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02912884` - Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure
Recruiting	`NCT06351631` - A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)	Phase 3
Recruiting	`NCT01816022` - Myeloproliferative Neoplasms and Bone Structure	N/A
Active, not recruiting	`NCT05223920` - Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)	Phase 2
Terminated	`NCT00522574` - A Safety Study of XL019 in Adults With Myelofibrosis	Phase 1
Recruiting	`NCT04081220` - Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2	Phase 2
Completed	`NCT01134120` - A Study in Myeloproliferative Disorders	Phase 1